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Background: Dried blood spots (DBSs) are an attractive alternative to plasma for HIV-1 drug resistance
testing in resource-limited settings. We recently showed that HIV-1 can be efﬁciently genotyped from
DBSs stored at 2208 8 8 8 8C for prolonged periods (0.5–4 years). Here, we evaluated the efﬁciency of geno-
typing from DBSs stored at 48 8 8 8 8C for 1 year.
Methods: A total of 40 DBSs were prepared from residual diagnostic specimens collected from HIV
subtype B-infected persons and were stored with desiccant at 48 8 8 8 8C. Total nucleic acids were extracted
after 1 year using a modiﬁcation of the Nuclisens assay. Resistance testing was performed using the
ViroSeq HIV-1 assay and an in-house nested RT–PCR method validated for HIV-1 subtype B that ampli-
ﬁes a smaller (1 kb) pol fragment.
Results: Using the ViroSeq assay, only 23 of the 40 (57.5%) DBS specimens were successfully geno-
typed; 22 of these specimens had plasma viraemia >10 000 RNA copies/mL. When the specimens were
tested using the in-house assay, 38 of the 40 DBSs (95%) were successfully genotyped. Overall, resist-
ance genotypes generated from the DBSs and plasma were highly concordant.
Conclusions: We show that drug resistance genotyping from DBSs stored at 48 8 8 8 8C with desiccant is
highly efﬁcient but requires the ampliﬁcation of small pol fragments and the use of an in-house nested
PCR protocol with quality-controlled reagents. These ﬁndings suggest that 48 8 8 8 8C may represent a suit-
able temperature for long-term storage of DBSs.
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Introduction
The availability of clinical specimens that can be easily col-
lected, stored and transported is advantageous in areas that lack
appropriate infrastructure for blood processing. Whole blood
samples collected by ﬁnger stick and dried onto a ﬁlter paper
[dried blood spots (DBSs)] represent an attractive alternative to
the conventional collection of blood in tubes. DBSs have been
extensively used for HIV-1 antibody testing,
1 molecular diag-
nostics
2 and virus load (VL) quantiﬁcation
3–5and are now con-
sidered a convenient alternative to plasma for HIV-1 drug
resistance testing. We recently found that drug resistance
genotypes generated from DBSs were similar to those derived
from plasma in antiretroviral-naive and -experienced patients.
6,7
We also found that resistance testing from DBSs can be as sensi-
tive as with plasma when using a genotypic assay that ampliﬁes
a large (1.8 kb) pol fragment.
6 The high success of ampliﬁcation
was noted using DBSs stored at 2208C in the presence of desic-
cant, suggesting that 2208C may represent a feasible storage
temperature for DBSs. Although these ﬁndings were encoura-
ging, storage at 2208C is not always possible in resource-
limited settings where 48C or room temperature may represent a
more realistic alternative. Studies on HIV-1 VL determinations
using DBSs have reported the efﬁcient ampliﬁcation of short
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3,8,9 However, genotypic assays usually rely on the
ampliﬁcation of large pol fragments and are thought to be par-
ticularly sensitive to HIV-1 RNA degradation that may occur
under suboptimal storage conditions. Here, we report on the efﬁ-
ciency of ampliﬁcation and drug resistance genotyping from
DBSs stored at 48C for 1 year.
Methods
Preparation and storage of DBSs
We prepared a total of 40 DBSs from residual diagnostic specimens
collected from highly antiretroviral-experienced HIV-1 subtype
B-infected persons. A more detailed description of the study popu-
lation including antiretroviral drug treatment has been reported else-
where.
6 Drug resistance genotypes were available for the matched
plasma specimens.
6 The median plasma VL in these patients was
13 680 RNA copies/mL (range 518–676 694, Versant HIV-1 RNA
3.0 Assay, Bayer HealthCare Diagnostic Division, Tarrytown, NY,
USA) (Table 1). DBSs were prepared by pipetting 50 mL of whole
blood onto pre-marked circles on 903 ﬁlter paper cards (Schleicher &
Schuell, Keene, NH, USA). Cards were dried overnight at room
temperature (258C), placed in a gas-impermeable, sealable plastic bag
(Fisher Scientiﬁc Company, Pittsburgh, PA, USA) containing a silica
gel desiccant (Mini Pax Sorbent, Multisorb technologies, Buffalo,
NY, USA) and stored at 48C until they were shipped to CDC in dry
ice. Upon arrival, individual plastic bags were put in a larger bag
containing three extra desiccants and stored at 48C. All desiccants
were evaluated for humidity at 6 months; 21 of the 40 bags had evi-
dence of humidity as indicated by the colour indicator in the desic-
cant. Therefore, a new desiccant was added to each individual bag
after allowing the spots to equilibrate at room temperature for 30 min.
None of the specimens had mould after 12 months of storage at 48C.
Nucleic acid extraction
Total nucleic acids were extracted from one spot after 1 year of
storage at 48C using a modiﬁcation of the Nuclisens assay described
previously.
7 Brieﬂy, a whole spot containing 50 mL of blood was cut
with scissors and added into 9 mL of Nuclisens lysis buffer
(bioMe ´rieux, Inc., Durham, NC, USA). Special care was taken to
avoid contact of the scissors with the blood spots; scissors and forceps
were sprayed with 70% ethanol after each use and wiped dry. After
2 h of incubation with lysis buffer at room temperature under gentle
rotation, the supernatant was clariﬁed by centrifugation at 250 g for
5 min and then transferred to a clean 15 mL conical tube. Nucleic
acids were then extracted following the manufacturer’s instructions,
resuspended in 45 mL of elution buffer and stored at 2808C until use.
Drug resistance testing
Resistance testing from DBSs was performed using the ViroSeq
HIV-1 Genotyping System (Abbott Molecular, Des Plains, IL, USA)
and an in-house reverse transcriptase (RT)-nested PCR method
described previously.
7 The ViroSeq assay ampliﬁes a 1.8 kb pol
fragment and has a sensitivity of detection of 2000 RNA copies/mL
plasma. The in-house assay ampliﬁes a 1023 bp fragment of HIV-1
pol comprising amino acids 15–99 of the protease and 1–256 of
the RT. This assay has been validated only for HIV-1 subtype B
viruses and has a sensitivity of detection of 1000 RNA copies/mL
of plasma.
7 Genotypes were interpreted using the Stanford
Genotypic Resistance Interpretation Algorithm (version 4.2.6) avail-
able at http://hivdb.stanford.edu/pages/algs/HIVdb.html.
Results
When the ViroSeq assay was used, only 23 of the 40 (57.5%)
DBS specimens stored at 48C were successfully genotyped; 22
of the successful ampliﬁcations were from specimens that had
plasma viraemia .10 000 RNA copies/mL (Table 1). An
additional ﬁve specimens produced amplicons that did not gen-
erate full-length RT and protease sequences. Visual inspection
of the desiccant bags after 6 months of storage at 48C showed
evidence of humidity in 21 of the 40 specimens. Of these 21
specimens, only those with plasma VL higher than 14 000 RNA
copies/mL (12 specimens) were successfully genotyped by the
ViroSeq assay at 12 months (data not shown).
As we previously noted using parallel DBSs stored at 2208C,
resistance genotypes generated from DBSs and matched plasma
specimens were highly concordant. Of the 163 drug resistance
mutations identiﬁed in these 23 plasma sequences, 158 were also
found in sequences generated from DBSs. Of the ﬁve mutations
absent in DBSs, three were protease mutations, two were major
(V82A and I54M) and one minor (L10IT), and two were poly-
morphisms at codon 333 of the RT (G333E and G333D) (data
not shown). We also compared the efﬁciency of ampliﬁcation
seen in these DBSs with that previously seen in DBSs prepared
in parallel from the same patients and stored at 2208C for 6
months.
6 Under storage at 2208C, all of the 40 DBS specimens
were successfully ampliﬁed and genotyped (Table 1).
The ViroSeq assay ampliﬁes a large (1.8 kb) pol fragment in
a single round of PCR and may be particularly sensitive to the
degradation of HIV-1 nucleic acids that may occur during long-
term storage. We, therefore, assessed if the rate of ampliﬁcation
from DBSs stored at 48C could be improved by using an
in-house assay that ampliﬁes a smaller (1023 bp) fragment and
uses a nested PCR step.
7 Using this method, viruses from 38 of
the 40 DBSs (95%) were successfully genotyped (Table 1).
Despite the use of a different assay to genotype viruses from
these 38 DBS specimens, resistance genotypes were highly con-
cordant with those generated from plasma using the ViroSeq
assay; 275 of the 291 mutations found in plasma viruses were
also found in viruses from DBSs (data not shown).
To investigate if the decreased ampliﬁcation success rate
observed with the ViroSeq assay was due to insufﬁcient or
degraded HIV nucleic acids, we performed serial dilutions of
RNA extracts from high VL specimens and tested them by both
the in-house and the ViroSeq assays (Figure 1). Although both
assays have comparable sensitivity, ampliﬁcation signals were
only maintained when the shorter pol fragment was ampliﬁed by
the in-house method. Figure 1 shows that such signals were con-
sistently lost when the larger pol fragment was ampliﬁed using
the ViroSeq assay, suggesting the possibility of nucleic acid
degradation during storage at 48C. Such a possibility was further
supported by parallel testing of serial dilutions of RNA extracts
prepared from specimens stored at 2208C. Figure 1(c) shows that
ampliﬁcation signals generated from these specimens using the
in-house assay were generally stronger than those obtained from
the same DBS specimens stored at 48C (Figure 1b).
Discussion
Our study on a small number of specimens suggests that storage
at 48C may represent a feasible alternative to 2208C for
long-term storage of DBSs. However, we noted that the efﬁcient
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in-house nested PCR assay and that the ViroSeq assay failed to
genotype a substantial proportion of specimens. The results with
the ViroSeq assay differed from our previous ﬁndings with this
assay showing a high success of genotyping from DBSs stored
at 2208C and suggest that some degradation of RNA may have
occurred during long-term storage at 48C possibly due to subop-
timal storage temperature, humidity or both. Such a possibility
was suggested by the weaker ampliﬁcation signals observed in
RNA extracts from specimens stored at 48C compared with
those stored at 2208C upon serial dilutions. Although different
efﬁciencies of RNA extraction could partially explain these
differences, we found that a high proportion of the specimens
stored at 48C had evidence of humidity at 6 months, whereas
none of the specimens stored at 2208C did. High humidity con-
ditions are thought to be detrimental to resistance testing from
DBSs given the extreme sensitivity of HIV nucleic acids to
degradation in the presence of humidity.
10 Nonetheless, we
showed that it is possible to overcome potential losses in HIV-1
RNA integrity and efﬁciently genotype from DBSs stored at 48C
Table 1. Frequency of ampliﬁcation of HIV-1 pol from plasma or DBSs stored at 2208C for 6 months or at 48C for 12 months
Specimen
ID
Plasma VL (log10
copies/mL)
CD4 cells/
mm
3 Plasma
a
DBS (2208C, 6 months,
ViroSeq assay)
b
DBS (48C, 12 months,
ViroSeq assay)
DBS (48C, 12 months,
in-house assay)
1 676 694 32 þþ þ þ
2 266 612 195 þþ þ þ
3 214 330 195 þþ þ þ
4 191 674 48 þþ þ þ
5 170 289 663 þþ þ þ
6 90 758 324 þþ þ þ
7 63 261 169 þþ þ þ
8 51 598 324 þþ þ þ
9 52 342 457 þþ þ þ
10 49 805 450 þþ þ þ
11 37 010 152 þþ þ þ
13 30 267 525 þþ þ þ
14 28 742 378 þþ þ þ
16 23 352 221 þþ þ þ
17 23 321 168 þþ þ þ
18 21 896 391 þþ þ þ
19 17 563 289 þþ þ þ
20 16 359 609 þþ n.s þ
21 14 622 483 þþ þ þ
22 13 952 396 þþ þ þ
23 13 407 224 þþ þ þ
24 12 452 374 þþ 2 þ
25 12 307 465 þþ þ þ
26 12 264 1320 þþ þ þ
27 11 999 81 þþ 2 þ
28 11 663 336 þþ n.s þ
29 10 998 442 þþ n.s. 2
30 9955 342 þþ 2 þ
31 8316 288 þþ 2 þ
32 4717 þþ 2 þ
33 4349 990 þþ 2 þ
34 4213 1080 þþ 2 þ
36 3880 434 þþ n.s. þ
37 3455 468 þþ 2 þ
38 2240 154 þþ þ þ
39 1929 416 þþ 2 þ
42 1254 858 þþ 2 n.s.
44 1045 360 þþ 2 þ
45 929 63 þþ n.s. þ
46 518 240 þþ 2 þ
n.s., HIV-1 RT and protease were ampliﬁed but failed to generate full-length sequences.
aPlasma genotypes were generated using the Viroseq assay except for 1, 3, 18, 32, 33, 39 and 42 (TrueGene assay).
bAmpliﬁcation from these DBSs stored at 2208C has been reported elsewhere.
6
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smaller fragment using stringent, quality-controlled reagents.
These results are encouraging and expand on our earlier ﬁndings
showing the efﬁcient genotyping of HIV-1 pol from DBSs
stored at 2208C for up to 4 years.
6,7 A high success of genotyp-
ing has also been noted from DBSs stored for 3 months at 378C
and 85% humidity in the presence of desiccant.
10 Under these
extreme conditions, viruses from  85% of the DBS specimens
could be genotyped by using in-house nested PCR assays that
ampliﬁed small (700 bp), overlapping pol sequences.
10 The use
of nested PCR protocols and/or the ampliﬁcation of small frag-
ments may likely result in higher ampliﬁcation success rates
from DBSs stored under less optimal conditions. Such a possi-
bility was supported by our ﬁndings, showing a better mainten-
ance of ampliﬁcation efﬁciencies using the in-house method
upon serial dilution of RNA extracts. Despite having comparable
sensitivity, ampliﬁcations were rapidly lost when a larger frag-
ment was ampliﬁed using the ViroSeq assay.
The main objective of our study was to evaluate the ampliﬁ-
cation success rate from DBSs stored at 48C for a prolonged
period of time. We used an in-house assay validated for HIV-1
subtype B since our study population included patients infected
with subtype B viruses. It is important to note, however, that
information on the performance of our assay with non-B sub-
types is limited to a small number of specimens.
7 Therefore, we
caution that resistance testing from DBSs collected in areas with
prevalent non-B subtypes will require in-house assays appropri-
ately validated for other HIV subtypes.
The ability to collect blood samples on ﬁlter paper represents
an advantage for HIV drug resistance surveillance and monitor-
ing, particularly in areas that lack the appropriate infrastructure
for plasma processing and transport. Much effort is currently
underway to deﬁne the best conditions that will facilitate resist-
ance testing from DBSs including the most appropriate storage
temperature and time. The ﬁndings reported here suggest that
48C may represent a feasible storage temperature for long-term
storage of DBSs and add to the promise of DBSs as a con-
venient specimen type for HIV-1 drug resistance testing.
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Figure 1. Agarose gel showing the HIV-1 pol ampliﬁcation signals obtained
from DBS specimens stored at 4 or 2208C. Two serial 10-fold dilutions (1/10
and 1/100) of specimens 2 (266 612 RNA copies/mL), 3 (214 330 RNA
copies/mL), 4 (191 674 RNA copies/mL) and 10 (49 805 RNA copies/mL)
were prepared in Nuclisens elution buffer and were tested in parallel using the
ViroSeq assay (1.8 kb) or the in-house RT-nested PCR method (1023 bp). (a)
DBS specimens stored at 48C and ampliﬁed using the ViroSeq assay. (b) DBS
specimens stored at 48C and ampliﬁed using the in-house method. (c) DBS
specimens stored at 2208C and ampliﬁed using the in-house method.
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